Bactana Receives Prestigious Grant From the National Science Foundation

February 24, 2022

Bactana Corp. today announced the company has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I grant that will enable expanded research and development efforts for its leading therapeutic candidate, FPZ-100.

FPZ-100 is a patent pending technology comprised of peptides and metabolites derived from F. prausnitzii, an important commensal bacteria present in human and animal microbiomes. Since 2017, Bactana’s research efforts have focused on developing oral feed additives to improve feed efficiency and reduce antibiotic usage during livestock production. However, recent trials have shown that oral dosing of FPZ-100 significantly reduces diabetic and prediabetic blood markers in mice without causing undesirable hypoglycemic side effects.

Read more.